Dr. Sam Gandy: “Roche Reports Mixed Results in Trial of an Alzheimer’s Drug”
Roche, the pharmaceutical company, on Wednesday reported mixed results in its latest trial of an Alzheimer’s drug. It said that while the drug did not slow progression of the disease over all, at the highest doses it did seem to delay a decline in mental ability in patients with mild cases of Alzheimer’s. “Long story short, we are still a long way from anything that could be approvable as therapy,” said Sam Gandy, PhD, Professor of Neurology and Psychiatry, and Associate Director of the Mount Sinai Alzheimer’s Disease Research Center at the Icahn School of Medicine at Mount Sinai. Learn more

Scientists Develop Novel Approach to Enhance Drug Delivery for Brain Tumors in Children
Mar 02, 2023 View All Press Releases
Researchers Identify the Role of an Alzheimer’s Disease Risk Gene in the Brain
Nov 30, 2022 View All Press Releases